We serve 1-chloro-4-methoxybutane CAS:17913-18-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: 1-chloro-4-methoxybutane
CAS.NO:17913-18-7
Molecular Formula:C5H11ClO
Molecular Weight:122.59300
Synonyms:
4-Chlorobutyl methyl ether
1-Chloro-4-methoxybutane
4-(methoxy)-1-chlorobutane
4-Methoxybutyl Chloride
Butane,1-chloro-4-methoxy
4-chloro-1-methoxybutane
Ether,4-chlorobutyl methyl
1-chlor-4-methoxybutan
methyl 4-chlorobutyl ether
Physical and Chemical Properties:
Density: 0.951 g / cm3
Boiling point: 138.3ºC at 760 mmHg
Flash point: 47.8 ± 17.9 ° C
Refractive index: 1.408
Specification:
Appearance:Colorless liquid
Purity:≥99.0%
Moisture Content: <0.1%
Impurity: <0.4%
Loss On Drying: 0.2%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place.
Application:
Pharmaceutical Intermediates, APIs,fluvoxamine maleate intermediate.
Contact us for information like 1-chloro-4-methoxybutane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 4-chlorobutyl ether physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Methoxybutyl Chloride Use and application,4-chloro-1-methoxybutane technical grade,usp/ep/jp grade.
Related News: Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.2-Amino-6-methylphenol manufacturer Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.benzo[b]naphtho[2,3-d]furan-5-boronic acid supplier For example, an active ingredient to relieve pain is included in a painkiller.trans-4-Methylcyclohexylamine hydrochloride vendor The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries.The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries.
